Trial Search Results

Transplantation for Patients With Chronic Lymphocytic Leukemia

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
  • Procedure: ablative allogeneic hematopoietic cell transplant




Inclusion Criteria:- adequate organ function - normal bone marrow cytogenetics

Exclusion Criteria:- active CNS disease

- For autologous patients more than 30% bone marrow involvement

Ages Eligible for Study

18 Years - 60 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting